AC Immune SA (ACIU) AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
AC Immune S.A. NASDAQ:ACIU Healthcare · Biotechnology
AH Close $2.31 +0.00% vs close
AH Close $2.31 +0.00% vs close
All Press Release SEC Filings News
SEC Filing
ACIU: 6-K · leadership change
AC Immune SA held an Extraordinary General Meeting on October 2, 2026, where shareholders approved the election of Tom Graney as a Member of the Board of Directors.
Graney will serve until the end of the Annual General Meeting 2027, with full voting details to appear in the minutes published on AC Immune's investor relations website within 15 days.
The filing is a routine governance disclosure with no financial or strategic implications; the report is incorporated by reference into AC Immune's existing F-3 and S-8 registration statements.
SEC 6-K • 24d ago AI analysis › Press Release ● Major ⚠ 2
AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
AC Immune reported positive week-100 results from Part 1 of the VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson's disease, with all primary endpoints of safety, tolerability and immunogenicity met.
100% of treated patients developed antibodies against the a-syn target after three immunizations, with robust antibody penetration into the CSF and preliminary signals of target engagement.
Part 2, designed to show clinical activity as the basis for a Phase 3 decision, is being finalized, with FDA meetings expected early 2027.
• 1mo ago AI analysis › SEC Filing ⚠ 3
ACIU: 6-K · leadership change
AC Immune SA filed a 6-K announcing an Extraordinary General Meeting on October 2, 2026 in Lausanne, where shareholders will vote on a single agenda item: electing Tom Graney to the Board of Directors and the Audit and Finance Committee. The EGM invitation and proxy cards were published September 2, 2026, with the Board recommending a vote FOR the proposal.
Graney brings more than 25 years of biopharma experience, including CFO roles at Vertex Pharmaceuticals, Ironwood Pharmaceuticals and Generation Bio and a long career at Johnson & Johnson, and most recently served as CFO then CEO of Oxurion. He previously sat on AC Immune's board from 2016 to 2023 and has helped raise more than USD 500 million across private and public capital markets.
Separately, Carl June is stepping down from the Board and Audit and Finance Committee effective at the EGM, a decision the company said was not due to any disagreement. The board refresh comes as AC Immune manages a leadership transition following co-founder Andrea Pfeifer's retirement, with Martin Zügel serving as Chair and Interim CEO.
SEC 6-K • 1mo ago AI analysis › Press Release
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune reported positive interim data from a Phase 1 study of its oral NLRP3 inhibitor ACI-19764, demonstrating that the drug was safe and well-tolerated with a serum half-life greater than 30 hours.
Preliminary results confirmed cerebrospinal fluid penetration and dose-dependent inhibition of IL-1beta release, with therapeutic doses expected to be 10mg or less once daily.
The trial has commenced dosing in a cardiovascular risk cohort, with initial results expected by year-end and full Phase 1/1b data anticipated in the first half of 2027.
• 2mo ago AI analysis › Press Release ● Major
AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
AC Immune secured FDA Fast Track designation and IND clearance for ACI-7104, an active immunotherapy targeting alpha-synuclein for early-stage Parkinson's disease.
The designation is supported by interim Phase 2 data from the VacSYn trial, which demonstrated safety, tolerability, and a 100% immunogenicity responder rate at 76 weeks.
Full week-100 results from Part 1 of the study are expected in the second half of 2026, supported by a recently awarded $4 million research grant.
• 2mo ago AI analysis › SEC Filing ⚠ 3
ACIU: 6-K · periodic report
AC Immune SA furnished its half-year 6-K for the six months ended June 30, 2026, reporting a net loss of CHF 12.9 million (CHF 0.13 per share), a sharp improvement from the CHF 40.2 million loss (CHF 0.40 per share) in the year-ago period.
Liquidity totaled CHF 27.8 million in cash plus CHF 47.6 million in short-term financial assets at June 30, 2026, with CHF 17.0 million of investment maturities converted during the half and no going-concern language disclosed.
On the pipeline, the Phase 2 VacSYn trial of ACI-7104 in Parkinson's disease has randomized over 30 patients, and December 2025 interim data showed strong antibody responses with biomarker signals suggesting possible disease modification; final Part 1 results are due in H2 2026, alongside ACI-19764 Phase 1 readouts.
Partnered programs with Takeda (ACI-24 in the ABATE Phase 1b/2), Janssen (ACI-35 Phase 2b), and Lilly (intracellular Tau small molecules) provide external validation while the wholly-owned assets advance toward key H2 2026 catalysts.
SEC 6-K • 2mo ago AI analysis › Press Release ● Major ⚠ 1
AC Immune First Half 2026 Financial and Corporate Update
AC Immune reported H1 2026 revenue of CHF 16.2 million, a seven-fold increase from the prior year, driven by milestone payments from partners Lilly and Takeda.
The company narrowed its net loss to CHF 12.9 million and holds CHF 75.4 million in cash, which provides funding into Q4 2027.
Near-term catalysts include H2 2026 data readouts for the wholly-owned ACI-7104 and ACI-19764 programs; Dr. Martin Zügel has succeeded Dr. Andrea Pfeifer as interim CEO.
• 2mo ago AI analysis › Press Release
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune announced three data presentations at the Alzheimer's Association International Conference (AAIC) 2026, focusing on its Morphomer-based pipeline for neurodegenerative diseases.
The company will showcase early human imaging data for the first-in-class TDP-43 PET tracer [18F]ACI-19626 and Phase 1 results for the NLRP3 inhibitor ACI-19764.
Additionally, data on the alpha-synuclein Morphomer program will demonstrate neuroprotective effects in vivo.
• 3mo ago AI analysis › SEC Filing ⚠ 1
ACIU: 6-K · clinical trial
AC Immune SA reported interim 12-month data from the Phase 1b/2 ABATE trial showing ACI-24 was generally safe and well-tolerated with no evidence of ARIA-E in the first three cohorts. Anti-Abeta antibody responses were detected at all dose levels, demonstrating a dose response across the 74 patients evaluated.
Based on the results, the company initiated the AD4 cohort to test ACI-24 with an additional adjuvant designed to enhance immunogenicity and improve plaque removal. This progression triggered a $12 million milestone payment from partner Takeda under the terms of their worldwide license agreement.
SEC 6-K • 3mo ago AI analysis › SEC Filing
ACIU: 6-K · proxy statement
AC Immune SA held its Annual General Meeting on June 11, 2026, where shareholders approved the 2025 financial statements, which reported an IFRS net loss of CHF 70.4 million and statutory net loss of CHF 67.6 million. The company’s accumulated losses increased to CHF 424.4 million, reflecting its ongoing clinical-stage burn rate, though it maintains a cash position of CHF 74.8 million (approx. USD 94 million) providing a runway into Q4 2027.
Shareholders endorsed the compensation report and approved maximum aggregate compensation caps of CHF 1.03 million for the Board and CHF 6.74 million for Executive Management for the upcoming period. The Board of Directors, including Interim CEO Martin Zügel and notable members Carl June and Roy Twyman, was unanimously re-elected, and PricewaterhouseCoopers was re-appointed as statutory auditor.
The meeting also approved a new capital band allowing the Board to adjust share capital between CHF 2.2 million and CHF 2.8 million until June 2031, and increased the conditional share capital for employee benefit plans to CHF 150,000. These governance actions are routine and signal stability in the company’s capital structure and leadership during its clinical development phase.
SEC 6-K • 4mo ago AI analysis › Press Release
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
AC Immune announced a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to support the development of ACI-7104 in early Parkinson’s disease.
The funds will extend Part 1 of the ongoing Phase 2 VacSYn trial by two years to assess long-term safety and efficacy, with final data expected in the second half of 2026.
This non-dilutive funding reinforces the company’s pipeline progress following positive interim results reported in December 2025, which suggested potential disease-modifying effects.
• 4mo ago AI analysis › Press Release
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune presented new Phase 1 data for its TDP-43 PET tracer ACI-19626, showing significantly higher uptake in the brains of ALS patients compared to healthy controls.
The results, presented at the 2026 TDP43 Summit, confirm the tracer’s ability to detect TDP-43 pathology in key brain regions like the brain stem and precentral gyrus, consistent with post-mortem studies.
This data expands on previous findings in frontotemporal dementia (FTD) and supports the company’s precision medicine platform for early diagnosis of neurodegenerative diseases.
• 5mo ago AI analysis › SEC Filing ⚠ 4
ACIU: 6-K · leadership change
AC Immune SA announced that founding CEO Dr. Andrea Pfeifer will retire after 23 years, with Board Chair Dr. Martin Zügel appointed as Interim CEO effective immediately. This leadership transition coincides with the company’s Annual General Meeting invitation, which includes proposals for board re-elections and compensation approvals.
The filing highlights positive clinical progress, specifically interim results for ACI-7104 in Parkinson’s disease showing potential disease modification, and a new CHF 10 million payment from Eli Lilly for its Tau Morphomer program. These scientific milestones provide a constructive backdrop to the executive change.
Financially, AC Immune reported a net loss of CHF 70.4 million for fiscal year 2025. The company maintains a cash runway into Q4 2027 following a 30% workforce reduction in late 2025, and shareholders will vote on a new capital band allowing flexible equity issuance until 2031.
SEC 6-K • 5mo ago AI analysis › Press Release
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
globenewswire.com • 5mo ago Press Release ● Critical ⚠ 1
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
Dr. Andrea Pfeifer, the co-founder and CEO of AC Immune, will retire after 23 years of service, effective at the upcoming AGM.
Dr. Martin Zügel, the Board Chair, will be appointed interim CEO to lead the company during the transition period.
Dr. Pfeifer will continue to support the company as an Advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board.
AC Immune is well-positioned with a robust balance sheet and multiple near-term value-inflection milestones, including strategic partnerships with Eli Lilly, Takeda, and Johnson & Johnson.
• 5mo ago AI analysis › Press Release
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune dosed the first patients in Cohort AD4 of the Phase 1b/2 ABATE trial, triggering a $12 million milestone payment from partner Takeda.
The trial evaluates ACI-24 for Alzheimer's prevention, with 12-month data from earlier cohorts expected in Q2 2026.
Takeda holds an option to assume further development, with AC Immune eligible for up to $2.1 billion in potential milestones under the existing agreement.
• 5mo ago AI analysis › Recent SEC filings with analysis 
